TFR refers to a sustained deep molecular response, typically indicated by a 4 or 4.5 log reduction in the BCR-ABL1 gene transcript levels, maintained for a defined period (often at least 2 years) following the cessation of TKI therapy in CML patients. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.